Overview Budesonide 9 mg Capsules in Active UC Status: Completed Trial end date: 2017-03-01 Target enrollment: Participant gender: Summary The purpose of the trial is to evaluate the efficacy of an 8 week treatment with once-daily 9 mg budesonide in patients with active ulcerative colitis Phase: Phase 2 Details Lead Sponsor: Dr. Falk Pharma GmbHTreatments: Budesonide